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Chronic infection with hepatitis C virus (HCV) is a major cause of liver disease-related death and is also the most frequent
indication for liver transplantation in USA. Infected individuals can remain asymptomatic for 20 years or more, but they remain
at risk for progressive liver disease. They also represent a potential source of infection for others. For reducing the future disease
burden due to HCV, obstetrician/gynecologists and primary health care practitioners should be aware of the factors that promote
HCV transmission: how to provide counseling and testing, and when specialist referral is needed.
Copyright © 2008 Bernard Gonik. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Hepatitis C virus (HCV) is transmitted mostly via infected
bloodorbloodproducts[1]andisthemostprevalentblood-
borne virus in the United States, where an estimated 3.2
million people are chronically infected [2, 3]. Worldwide
prevalence is estimated to be 170 million [4]. It is a single-
stranded RNA virus of the family Flaviviridae. The viral
genomeshowsgreatvariabilityinnucleotidesequenceowing
to a high rate of mutation [3]. There are 6 major HCV
genotypes and more than 50 subtypes [3]. This variation is
believedtopartlyaccountfortheabilityofthevirustoescape
host immune defenses and sustain a chronic infectious state
[3, 5].
The acute stage of HCV infection is only infrequently
associated with symptoms of hepatitis such as anorexia,
weakness, malaise, and jaundice [3]. It usually goes undiag-
nosed. Chronic infectionis deﬁnedasinfection persisting for
longer than 6 months [3]. In most instances, HCV infection
remains undetected until a chronic stage and is discovered
during the course of testing for an unrelated condition
or during blood donation [6]. It is estimated that acute
infection develops into chronic infection in 60% to 85% of
cases. Younger age, female sex, non-African-American race,
and certain histocompatibility genes are all associated with
improved spontaneous clearance of the virus and a lower
likelihood of chronic infection [3].
HCV has been found in all regions of the world where it
has been sought [4]. Approximately, 1.3% of the population
of the United States is chronically infected [2]. Areas of
higher prevalence include certain countries in the Far East,
Mediterranean, Africa, and Eastern Europe. This worldwide
reservoir of infection remains a potential source for new
infections [4]. Most of the morbidity and mortality from
HCV is the result of long-standing chronic infection. Of
those chronically infected with HCV, approximately 5% of
individuals aged <40 years and 34% to 58% of individuals
aged ≥40 years develop cirrhosis of the liver 20 years
after exposure and may ultimately die from end-stage liver
disease or hepatocellular carcinoma [7]. In the United
States, approximately 40% of chronic liver disease is HCV-
related, which would suggest that 8000 to 10000 deaths each
year are caused by HCV. In addition, HCV-associated end-
stage liver disease is the most frequent indication for liver
transplantation in adults [1].
The estimated incidence of new infections in the United
States declined from 230000 in the mid-1980s to 36000
in 1996 [1]. The use of eﬀective HCV tests has largely
eliminated blood transfusion as a route of infection in
the United States and other developed countries [1]. In
addition, measures aimed at reducing the spread of human
immunodeﬁciency virus (HIV) may be responsible for the
observed reduction in new HCV infections in injection-drug
users [8]. However, because liver disease is the result of2 Infectious Diseases in Obstetrics and Gynecology
long-standing infection, the burden of disease continues to
rise. It is anticipated that there will be a 4-fold increase in the
number of Americans at risk of chronic liver disease in 2015
compared with 1990 [8].
2. RISK FACTORS FOR HCV INFECTION
Persons at the greatest risk of HCV infection are those who
have ever injected illicit drugs and those who have received
blood transfusions or organ transplants before universal
testing of donors was established. Also at risk are persons
who received clotting factor concentrates. Lesser but still
measurable risk factors for HCV include birth from an
infected mother, sexual contact, accidental contamination
during medical procedures, and household contact [1].
2.1. Parenteraltransmission
Injection-drug users are at extremely high risk of acquiring
HCV infection. It has been shown that the prevalence of
HCV among older injectors (≥5 years of injection) is high
(80% to 90%), whereas studies of young injectors (1–3
years of injection) in the last 10 years have shown that
the cumulative infection rates have slowed [9]. Only 20%
to 40% of young injectors are positive for HCV infection
[10]. Injection-drug users become more rapidly infected
with HCV than with other blood-borne viruses, possibly
because of high levels of HCV chronicity in this population
[11]. Injection-drug use accounts for most of the current
transmission of HCV in the United States [1].
Persons who received blood transfusions or organ trans-
plants before 1992 are considered to be at risk of having
acquired HCV infection. In the United States, introduction
of second-generation polyantigen testing from July 1992
largely eliminated the risk from donated blood and organs
[1].
2.2. Perinataltransmission
The average rate of infection in infants born to infected
mothers is 5% to 6%. The chance of infection has been
shown to be greater with higher serum levels of HCV-RNA
(17%) and in mothers coinfected with HCV and HIV (14%).
HCV-RNA can be detected within 2 to 3 months of birth [1].
Children with HCV infection only rarely show symptoms or
signiﬁcant elevations in liver enzymes. Progression to severe
liver disease is generally slower than in adults [12].
2.3. Sexualtransmission
The relevance of sexual transmission to the epidemiology of
HCV remains controversial. Epidemiologic surveys suggest
that 20% of patients with recently acquired hepatitis C
have no self-reported risk factor other than multiple sexual
partners or an infected sexual partner [13]. However, studies
of HCV transmission in stable monogamous couples show
very low rates of infection—in some instances, below the
detection limits of the study [14–18]. Most studies of couples
have been cross-sectional in design and have investigated
concordanceratesforseropositivity.Onlysomeofthestudies
included nucleotide sequencing; in these instances, HCV
strains were sometimes found to be too dissimilar to be
consistent with transmission between partners [19]. The rate
of sexual transmission between monogamous heterosexual
partners has been estimated to be between 0% and 0.6%
annually [3, 19]. This low rate of HCV infection after many
years of sexual exposure would suggest that the risk of sexual
transmission of HCV is minimal. It is biologically plausible
that rates of sexual transmission of HCV may be higher
if exposure to blood occurs, and there is some supporting
evidence for an association of acute HCV infection with
genital ulcers or sexual activity at risk for lacerations of
the anal epithelium [20, 21]. However, it is now widely
believed that the observed association of HCV with high-
risk sexual practices is mostly the confounding eﬀect of
unreported injection-drug use that is itself associated with
high-risk sexual practices [1]. Many persons are unwilling to
admit to a history of injection-drug use [22]. It should be
emphasized that the association between markers of high-
risk sexual practices and HCV infection is real, even if the
underlying reasons are unclear. The Centers for Disease
Control and Prevention (CDC) states that “although HCV
is not eﬃciently transmitted sexually, persons at risk for
infection through injection-drug use might seek care in STD
[sexually transmitted disease] treatment facilities” [23].
2.4. Nosocomialtransmission
In the United States and other industrialized countries, the
use of standard (universal) precautions to prevent infection
has eliminated most HCV transmission in health care set-
tings. Three exceptions remain. First, the average incidence
of seroconversion after needle stick or sharp exposure from
an HCV-seropositive source has been estimated to be 1.8%
(range 0% to 7%) [1]. One study showed a 1.2% incidence
of seroconversion after injury from a hollow-bore needle
but no instances of seroconversion from injuries with sharp
objects or from contamination of mucosa or nonintact skin
[24]. Second, despite stringent infection-control precau-
tions, HCV outbreaks continue to occur in hemodialysis
centers. Epidemiologic surveys show that the prevalence of
seropositivity in patients in hemodialysis centers averages
10% and, in some centers, can be greater than 60% [1].
Third, during the last 15 years, there has been an increase
of iatrogenic HCV transmission not related to dialysis [25].
It is being recognized with increasing frequency that HCV
transmission is resulting from unsafe therapeutic injection
practices, such as contaminated multiple-dose medication
vials, saline bags from reinsertion of used syringes, and con-
taminated platforms for spring-loaded ﬁnger-stick devices
used to monitor blood glucose in multiple patients. Interest-
ingly, most of the instances occurred in developed countries,
such as Western and Northern Europe, the United States,
Australia, and Japan.
The CDC has hemodialysis and syringe/needle safety
guidelines to prevent nosocomial HCV transmission in
ambulatory healthcare settings [26]. The CDC recommendsBernard Gonik 3
the following routine precautions for the care of all hemodi-
alysis patients:
(1) patientsshouldhavespeciﬁcdialysisstationsassigned
to them, and chairs and beds should be cleaned after
each use;
(2) sharing among patients of ancillary supplies such as
trays,bloodpressurecuﬀs,clamps,scissors,andother
nondisposable items should be avoided;
(3) nondisposable items should be cleaned or disinfected
appropriately between uses;
(4) medications and supplies should not be shared




(6) clean and contaminated areas should be separated
(e.g., handling and storage of medications and hand
washing should not be done in the same area or
an area adjacent to where used equipment or blood
samples are handled).
The CDC recommends that all health care workers
(1) useasterile,single-use,disposableneedleandsyringe
for each injection and to discard them intact in an
appropriate sharps container after use;
(2) use single-dose medication vials, preﬁlled syringes,
and ampules when possible. Do not administer med-
ications from single-dose vials to multiple patients or
combine leftover contents for later use;
(3) if multiple-dose vials are used, restrict them to a
centralized medication area or for single patient use.
Never reenter a vial with a needle or syringe used on
one patient if that vial will be used to withdraw med-
ication for another patient. Store vials in accordance
with manufacturer’s recommendations and discard
if sterility is compromised;
(4) do not use bags or bottles of intravenous solution as
a common source of supply for multiple patients;
(5) use aseptic technique to avoid contamination of ster-
ile injection equipment and medications.
2.5. Householdtransmission
Nonsexual transmission of HCV between family members
may infrequently occur, presumably via percutaneous or
permucosal exposure to blood. HCV seropositivity concor-
dance rates average 4% in nonsexual household contacts,
including siblings and others [27, 28]. However, most such
studies did not use conﬁrmatory sequence analysis [28].
Moreover, many of the studies were conducted in areas
where transmission from contaminated medical equipment
is known to have occurred in the past, and this would
alternatively explain HCV concordance in families [1].
3. ANTIVIRAL THERAPY
The standard therapy for chronic HCV infection is a course
of weekly subcutaneous injections of pegylated interferon
alfa (PEG-IFN) combined with once-daily oral ribavirin [12,
29]. Duration of treatment is 48, 24, or 12 weeks, depending
on HCV genotype and other treatment prognostic factors.
The principal goal of treatment is a sustained virologic
response (SVR), deﬁned as elimination of detectable virus
during treatment and continued absence of virus 6 months
after the end of treatment [12]. Long-term followup of
patients in clinical trials has shown that an SVR usually
presageslong-termeradicationoftheinfectionandamarked
reduction in the histologic and biochemical markers of liver
disease [30, 31].
Pegylated interferon has a covalently attached water-
soluble polymer of polyethylene glycol that improves the
pharmacokinetic proﬁle over that of standard interferon and
allows for once-weekly dosing. Ribavirin is an antiviral drug
that is eﬀective against HCV only when combined with
interferon. Although PEG-IFN has a greater eﬃcacy than
older anti-HCV therapies, it remains less eﬀective against
HCV genotype 1 than genotypes 2 and 3 [29]. Safety and
eﬃcacy of PEG-IFN have also been established in patients
with HCV and compensated cirrhosis and in patients with
HCV/HIV coinfection [32].
PEG-IFN can cause bone marrow suppression, and
ribavirin can cause hemolytic anemia, resulting in the need
for periodic hematologic testing during therapy. Thyroid
function testing (thyroid stimulating hormone) is required
because of the risk of autoimmune thyroiditis [29]. Emo-
tional side eﬀe c t so fi n t e r f e r o na r ec o m m o n[ 29], and
patientsneedtobemonitoredfordepression.Patientsshould
be advised to report any sign or symptom of depression to
their prescribing physician [32]. Ribavirin is contraindicated
in pregnancy and in male partners of pregnant women.
Thus pregnancy testing is required in women of childbearing
potential immediately before and at monthly intervals
during therapy. Women of childbearing potential and their
male partners must use reliable forms of contraception if
either partner is receiving PEG-INF/ribavirin, both during
treatment and for at least 6 months after treatment has
concluded [32].
For those individuals infected with the HCV virus, the
CDC recommends treatment based on the level of clinical
risk (Table 1). Treatment is generally recommended for
patients who are at an increased risk of developing cirrhosis
[29]. Such patients are characterized by detectable viremia,
and a liver biopsy shows portal or bridging ﬁbrosis and
moderateinﬂammationandnecrosis[3].Somepatientswith
milder disease than this also choose to be treated [3]. About
one third of those with chronic HCV have a highly favorable
prognosis and are unlikely ever to develop cirrhosis [33].
An informed choice between starting or deferring treatment
is based on prognostic factors, the likelihood of treatment
success, the potential for side eﬀects, any relative or absolute
contraindications, and on the patient’s motivation [3, 34].
Patients deferring antiviral therapy should undergo a liver
biopsyevery4or5yearstomonitordiseaseprogression[12].4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Treatment groups for patients with hepatitis C virus (HCV) [1].
Individuals recommended for treatment
(i) Patients with persistently elevated alanine aminotransferase (ALT) levels
(ii) Patients with detectable HCV ribonucleic acid
(iii) Patients with a liver biopsy indicating either portal or bridging ﬁbrosis or at least moderate degrees of inﬂammation and necrosis
Individuals for whom treatment is unclear
(i) Patients with compensated cirrhosis (without jaundice, ascites, variceal hemorrhage, or encephalopathy)
(ii)PatientswithpersistentALTelevationsbutwithlessseverehistologicchanges(i.e.,noﬁbrosisandminimalnecroinﬂammatorychanges)
(Inthesepatients,progressiontocirrhosisislikelytobeslow,ifatall;therefore,observationandserialmeasurementsofALTandliverbiopsy
every 3–5 years is an acceptable alternative to treatment with interferon)
(iii) Patients <18 years of age or >60 years of age (note that interferon is not approved for patients younger than 18 years)
Individuals for whom treatment is not recommended
(i) Patients with persistently normal ALT values
(ii) Patients with advanced cirrhosis who might be at risk for decompensation with therapy
(iii) Patients who are drinking excessive amounts of alcohol or who are injecting illegal drugs (treatment should be delayed until these
behaviors have been discontinued for ≥6m o n t h s )
(iv) Persons with major depressive illness, cytopenias, hyperthyroidism, renal transplantation, evidence of autoimmune disease, or who are
pregnant
4. SCREENING AND DIAGNOSIS
Obstetrician/gynecologists and other providers of primary
health care services can screen for patients at risk of
HCV infection, perform an initial diagnostic workup, and
provide appropriate counseling to those infected or at risk
of becoming infected. Routine screening of all adults is not
recommended; instead, screening is focused on individuals
withknownriskfactorsforHCVinfection[1].Theseinclude
the following:
(1) persons who have injected illegal drugs, even if this
took place in the remote past; this includes those
who injected once or a few times [1]; many of these
personsmaynotconsiderthemselvestobedrugusers
[22];
(2) persons who received an organ transplant or blood
transfusion before July 1992, when second-gener-
ation enzyme immunoassay (EIA) anti-HCV test-
ing was introduced [1]; women who had cesarean
sections before that date may have been at risk of
infection via transfusion;
(3) persons notiﬁed that they received blood from a
donor who later tested positive for HCV [1];
(4) persons who received clotting factor concentrates
produced before 1987, when heat inactivation was
introduced [1];
(5) persons who have ever been on long-term hemodial-
ysis [1];
(6) persons with HIV infection [1];
(7) patients with biochemical or clinical evidence of liver
disease, for example, persistent elevations of alanine
aminotransferase (ALT) [1, 29];
(8) health care, emergency medical, and public service
workers with needle stick injury or mucosal exposure
to HCV-positive blood [1];
(9) children born to HCV-infected mothers [1];
(10) current sexual partners of HCV-infected persons.
Although risk in this group is low, a negative test in
the partner provides reassurance [12].
Patients can be screened for risk factors during any visit. An
unexplained elevation of ALT may be caused by HCV, but
many of those with chronic HCV infection have normal ALT.
Signs and symptoms are sometimes present but are mostly
nonspeciﬁc and include malaise, anorexia, and fatigue; these
may be accompanied by low-grade fever and abdominal
discomfort. Physical examination may reveal signs of liver
disease such as hepatosplenomegaly, spider nevi, and palmar
erythema [35]. Counseling and testing should be oﬀered
if a risk factor is identiﬁed [1]. Testing for HCV is not
recommended for pregnant women without risk factors.
CertainsettingssuchasSTDclinicsandcorrectionalfacilities
serve large numbers of patients at high risk for blood-borne
infections, and it is especially important to screen for a
history of injection-drug use in these settings [23].
5. TESTING PROCEDURES
EIA tests are inexpensive, reproducible serologic tests that
detect anti-HCV antibodies. The version in current use
(third-generation) has high sensitivity and speciﬁcity, mak-
ing conﬁrmatory testing unnecessary in many instances. EIA
tests are recommended for initial testing of patients [3].
A positive test may be considered conclusive in patients
with evidence of liver disease, such as abnormally high
ALT, together with risk factors for infection [3]. Qualitative
polymerase chain reaction (PCR) tests detect viral RNA
with a greater sensitivity than the quantitative PCR tests
that are used to measure viral load. Qualitative PCR tests
can be used to conﬁrm a positive EIA. A negative PCR
result may require conﬁrmatory immunoblot testing for
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conﬁrmed anti-HCV test is suggestive of a spontaneously
cleared acute infection. Patients with immune deﬁciencies or
on hemodialysis may test false-negative for anti-HCV, and
patients with autoimmune disease may test false-positive. A
qualitative PCR test may be used as the primary test in these
instances [3]. Infants born to infected mothers should be
tested using EIA not earlier than 15 months of age to avoid
the possibility of a false-positive result caused by maternal
antibody. A PCR test can be performed during or after the
ﬁrst well-child visit at ages 1 to 2 months if an earlier result
is required [3].
6. COUNSELING
Obstetrician/gynecologists and other primary care physi-
cians can have an important role in counseling patients on
how to slow disease progression and prevent transmission of
the virus to others. Alcohol and HCV have independent and
synergistic eﬀects on the risk of cirrhosis [36]. Counseling
patients to eliminate or at least reduce alcohol consumption
may therefore be an eﬀective primary care intervention
for preventing progression to cirrhosis. Acceleration of
progression to cirrhosis has been clearly established with
heavy alcohol consumption, and the results of one study
suggest that moderate consumption may be deleterious [12,
37]. The CDC recommends that patients with chronic HCV
infection abstain from alcohol [1].
Counseling should also stress the importance of weight
control. Both obesity and its accompaniment, fatty liver
disease, are associated with progression of HCV-associated
liverdisease.Thusweightreductionforthosewithbodymass
index >25kg/m2 may be especially beneﬁcial in persons with
chronic HCV infection. Hepatitis A and B vaccinations are
recommended for all persons with chronic HCV infection
because of the increased risk of complications from coinfec-
tion, including fulminant hepatitis [12, 38].
Persons with HCV need reliable advice on how to
avoid transmitting the infection to others, and uninfected
persons need to know how to reduce the risk of infection.
Health care professionals should routinely obtain a history
that inquires about use of illegal drugs and evidence of
high-risk sexual practices (e.g., multiple sex partners or a
history of STDs) [1]. Knowing the risk factors and cross-
checking the patient’s history for these can have a positive
impact on prevention of HCV transmission. Guidance in
obtaining a sexual history is available from the curriculum
provided by CDC STD/HIV Prevention Training Centers
(http://www.stdhivpreventiontraining.org/)[ 23].
Current injection-drug users, regardless of HCV status,
should be advised to stop using and injecting drugs and
to enter and complete substance abuse treatment. If they
continue to inject, they must use only sterile needles and
syringes from a reliable source and never reuse or share drug
preparationequipment,plustheymustsafelydisposeofused
materials [1].
Primary prevention of illegal drug injection will elimi-
nate the greatest risk factor for HCV infection [1]. A study
showed that injection-drug users, even before they become
identiﬁed as high-risk by prevention services, may engage
in more high-risk practices than individuals who remain
nonusers [39]. Thus identifying risk factors for starting
injecting could increase the opportunities to intervene and,
in turn, cut transmission of HCV. Counseling and education
to prevent the initiation of drug-injection or high-risk sexual
practices is important, especially for adolescents [6].
Obstetrician/gynecologists should be aware that al-
though consistent data are lacking on the extent to which
sexual activity contributes to HCV transmission, persons
with multiple sex partners are at risk for STDs, including
HIV, human papillomavirus, hepatitis B virus, syphilis,
gonorrhea, and Chlamydia [1].
Obstetrician/gynecologistsshouldcounselpersonsatrisk
for STDs with regard to what they can do to minimize
their risk of becoming infected or of transmitting infectious
agents to others. Data on long-term sexual partners with no
other risk factors suggest that the rate of sexual transmission
of HCV is very low. Guidelines state that HCV-positive
individuals do not need to change their sexual practices
and that barrier forms of protection, such as condoms,
are not required [12, 23]. Although monogamous sexual
relationships carry a low risk of HCV transmission, the risk
is higher in HCV-infected individuals with multiple sexual
partners or in short-term relationships. In persons at risk for
sexually transmitted diseases, guidelines advise the correct
use of latex condoms during all sexual encounters [1].
HCV-positive women do not need to avoid pregnancy
or breastfeeding [1]. However, prospective and expectant
mothers concerned about HCV should be advised that
(1) routine testing for HCV is not recommended for
pregnant women unless there is a known risk factor
[1];
(2) approximately 5% of infants born to infected moth-
ers become infected at birth, and there is no known
treatment that can prevent this from happening. The
choice of cesarean versus vaginal delivery does not
appear to modify the risk of transmission [1];
(3) infants and children with HCV are less likely than
adults to have symptoms, and liver disease develops
more slowly. Spontaneous clearance of HCV is more
common in children than in adults [1, 12];
(4) available evidence suggests that breastfeeding does
nottransmitHCV,althoughmothersshouldconsider
avoiding breastfeeding if the nipples are cracked or
bleeding [1].
7. CONCLUSION
Hepatitis C and its associated liver disease is a global health
problem that is likely to increase in coming decades because
of a greater number of persons with long-standing chronic
infection. Antiviral therapies have improved in recent years
and can eradicate HCV infection in many individuals.
Because of the subclinical nature of chronic HCV, iden-
tiﬁcation of infected individuals who might beneﬁt from
therapy is central to the overall management of the disease.
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should be able to screen patients for risk factors and oﬀer
counseling and testing. All patients testing positive for HCV
are potential candidates for antiviral therapy and should
therefore be referred to specialists. Alcohol avoidance and
weight control may be eﬀective in delaying or preventing
the onset of cirrhosis in those who choose to defer antiviral
therapy.
Screening and counseling guidelines for hepatitis C that
emphasize the role of nonspecialists include CDC guidelines
on sexually transmitted diseases at http://www.cdc.gov/
std/treatment/default.htm, which has a section on hepatitis
C, and guidelines from the World Health Organization at
http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/
en/. Patient education leaﬂets on hepatitis C can be
located at the US Department of Veterans Aﬀairs at http://
www.hepatitis.va.gov/vahep?page=prtop02-00-rr#S16X and
at the National Library of Medicine Medline Plus at http://
www.nlm.nih.gov/medlineplus/hepatitisc.html.
Screening for HCV risk factors take place at any
health care visit. Obstetrician/gynecologists should note
that patients in certain settings, such as STD treatment
clinics, may be at increased risk of HCV infection. Sexual
transmission of HCV appears to occur only rarely in stable
monogamous couples, and precautions to prevent sexual
transmission are not needed in these circumstances. HCV
testing need not be oﬀered to pregnant women with no
identiﬁable risk factor; however, prenatal visits are a good
opportunity to screen for HCV risk factors and to oﬀer
testing and counseling where appropriate. This is in part
because health care visits may be more frequentthan at other
times in a woman’s life and also because of the need to follow
up children born to infected mothers.
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